Characteristics of US military personnel with atrial fibrillation and associated deployment and retention rates.

INTRODUCTION: Atrial fibrillation (AF) is an arrhythmia impacting military occupational performances. Despite being a recognised disqualifying condition, there is no literature describing US military service members with AF. This study aims to describe members with AF diagnoses, the distribution of treatment strategies and associated deployment and retention rates. METHODS: Active duty service members identified with AF from 2004 to 2019 were investigated. Cardiovascular profiles, AF management strategies and military dispositions were assessed by electronic medical record review. RESULTS: 386 service members (mean age 35.0±9.4 years; 94% paroxysmal AF) with AF diagnoses were identified. 91 (24%) had hypertension followed by 75 (19%) with sleep apnoea. Mean CHA2DS2-VASc scores were low (0.39±0.65). Rhythm treatments were used in 173 (45%) followed by rate control strategies in 155 (40%). 161 (42%) underwent pulmonary vein isolation (PVI). In subgroup analysis of 365 personnel, 147 (40%) deployed and 248 (68%) remained active duty after AF diagnosis. Deployment and retention rates did not differ between those who received no medical therapy, rate control or rhythm strategies (p=0.9039 and p=0.6192, respectively). PVI did not significantly impact deployment or retention rates (p=0.3903 and p=0.0929, respectively). CONCLUSION: Service members with AF are young with few AF risk factors. Rate and rhythm medical therapies were used evenly. Over two-thirds met retention standards and 40% deployed after diagnosis. There were no differences in deployment or retention between groups who receive rate therapy, rhythm medical therapy or PVI. Prospective evaluation of the efficacy of specific AF therapies on AF burden and symptomatology in service members is needed.

Reproductive strategy of the Patagonian catfish Hatcheria macraei.

This study describes the reproductive strategy of the stream-dwelling catfish Hatcheria macraei in the Pichileufu River, Argentina. Gonad maturity phases, classified on the basis of histological analysis, stages of gamete development and the frequency distribution of oocyte size, were correlated with macroscopic features of the gonads. Hatcheria macraei has a cystovarian ovary, asynchronous oocyte development and lobular testes. Five oocyte and four spermatogenic stages were identified and related to macroscopic gonad characteristics, making it possible to divide gonad development into five phases for females and males. Mature oocyte diameter ranged from 922 to 1935 µm. Absolute fecundity in mature females varied from 115 to 480 oocytes. Hatcheria macraei has multiple spawning during a protracted reproductive season that extends from December to April. This, together with its small size, is characteristic of an opportunistic reproductive strategy, commonly found in species that inhabit adverse and unpredictable environments, such as the low-order rivers of Patagonia.

Luteinizing hormone-releasing hormone fusion protein vaccines block estrous cycle activity in beef heifers.

Two LHRH fusion proteins, thioredoxin and ovalbumin, each containing seven LHRH inserts were tested for their ability to inhibit estrous cycle activity. The objective was to evaluate immune and biological responses from alternating the two fusion proteins in an immunization schedule. One hundred ten heifers were divided equally into 11 groups. Two control groups consisted of either spayed or intact, untreated heifers. Heifers in the other nine groups were immunized on wk 0, 4, and 9. Treatments were immunizations of the same protein throughout or alternating the proteins in different booster sequences. Blood was collected weekly for 22 wk, and serum was assayed for concentrations of progesterone and titers of anti-LHRH. At slaughter, reproductive tracts were removed from each heifer and weighed. Heifers with >or=1 ng/mL of progesterone were considered to have a functional corpus luteum and thus to have estrous cycle activity. All LHRH-immunized groups of heifers had a smaller (P < 0.05) proportion of heifers showing estrous cycle activity after 6 wk than the intact, untreated control group. There was no difference in number of heifers cycling between the immunized groups and the spayed heifers during wk 9 to 22. Anti-LHRH did not differ among immunized groups during wk 1 to 9. Starting at wk 10 and continuing through the conclusion of the study, there was an overall difference among treatment groups for anti-LHRH (P < 0.05). Uterine weights differed among treatments (P < 0.05), with intact control animals having heavier uteri than all other groups (P < 0.05). Uterine weights were negatively correlated with maximum LHRH antibody binding (r = -0.44). In summary, the LHRH fusion proteins were as effective as surgical spaying in suppression of estrous cycle activity, but alternating the two proteins in an immunization schedule did not enhance the immunological or biological effectiveness of the vaccine.

Endocrine, growth, and carcass characteristics of bulls immunized against luteinizing hormone-releasing hormone fusion proteins.

This study evaluated the effectiveness of a LHRH fusion protein vaccine on endocrine changes, feedlot performance, and carcass quality of bulls compared with steers and hormone-implanted steers. Crossbred bulls (n = 30; mean weight, 179 +/- 4 kg; mean age, 130 +/- 2 d) were randomly assigned to three treatment groups: 1) castrated (castrated; n = 10); 2) castrated-implanted with trenbolone acetate (implanted; n = 10); and 3) immunized against a cocktail of recombinant fusion proteins, ovalbumin-LHRH-7 and thioredoxin-LHRH-7 (immunized bulls; n = 10). Blood was collected every 2 wk to evaluate antibody and hormone concentrations. Serum LHRH antibodies (P < 0.001) were detected in animals of the immunized group, which had reduced serum LH concentrations (P < 0.001) compared with the castrated groups and serum FSH concentrations, which did not decrease but were significantly different when compared with castrated and implanted animals. Serum testosterone concentrations in the immunized bulls were not different from the two castrated groups (P > 0.05) by d 60 after primary immunization. Initial mean scrotal circumference of the immunized bulls was 18.0 +/- 0.6 cm on d 0 and increased to 22.6 +/- 1.3 cm by d 310. No differences (P > 0.05) in ADG were observed among treatment groups. Immunized animals had an intermediate BW gain (P > 0.05) when compared with the castrates, whereas the castrated groups differed (P < 0.05) from each other. Carcass characteristics were similar (P < 0.05) among the three groups. Vaccinating bulls against a LHRH fusion protein cocktail suppressed LH and testosterone, which led to reduced testicular development and no bullock carcasses. Growth and carcass characteristics of the immunized animals were similar to the steers.

Evaluation of American Wagyu sires for scrotal circumference by age and body weight.

Thirty-six percent of American Wagyu bulls do not meet the current minimum standards set by the Society of Theriogenology for the breeding soundness exam. In contrast, only 15% of bulls of domestic breeds do not meet the minimum standards. Scrotal circumference measurements of Wagyu are smaller than those of other breeds. The objective of this research was to describe scrotal circumference of Wagyu bulls as it relates to age and BW. The data set consisted of 190 Wagyu bulls housed at two locations. One hundred forty-one bulls constituted the first set of data (location 1); scrotal circumference was measured one to six times per bull aged between 13 and 70 mo. Ninety-four of the bulls underwent semen evaluation for motility and morphology. Forty-nine bulls constituted the data set for which scrotal circumference and BW was measured one to nine times per bull between 5 and 21 mo of age (location 2). Mean scrotal circumference of bulls within each age group was as follows: 12 to 14 mo, 29.8 0.2 cm (mean +/- SE); 15 to 17 mo, 31.8 +/- 0.2 cm; 18 to 20 mo, 32.9 +/- 0.3 cm; 21 to 24 mo, 31.8 +/- 0.5 cm; and > 24 mo, 35.5 +/- 0.2 cm. Both age and BW were highly correlated to scrotal circumference (r = 0.81 and 0.82, respectively). Within each age group, there were a percentage of bulls that did not meet the minimum standard for scrotal circumference set by the Society of Theriogenology. The percentages were as follows: 12 to 14 mo, 46%; 15 to 17 mo, 25%; 18 to 20 mo, 33%; 21 to 24 mo, 42%; and > 24 mo, 32%. Morphology and motility were > 50% each in 91% of the bulls between ages 12 and 20 mo at location 1. Based on these data, it is recommended that Wagyu bulls be evaluated with the breed-specific minimum standards for scrotal circumference of 26 cm from 12 to 14 mo, 29 cm from 15 to 17 mo, and 30 cm from 18 to 20 mo of age.

Technical note: recombinant LHRH fusion protein suppresses estrus in heifers.

A recombinant luteinizing hormone-releasing hormone (LHRH) fusion protein was evaluated for its effectiveness in suppression of estrus in heifers. Eight heifers were randomly assigned to two equal treatment groups. Treatments consisted of recombinant ovalbumin-LHRH-7 or recombinant ovalbumin (control). This recombinant chimeric fusion protein consisted of ovalbumin with seven LHRH peptides (ovalbumin-LHRH-7). The plasmid for this protein was expressed in E. coli and was collected and purified as an insoluble protein. One milligram of the respective proteins was suspended in 2 mL of Z-Max adjuvant and administered by intramammary injection three times at 7-wk intervals. Luteinizing hormone-releasing hormone antibody binding was elevated in heifers treated with ovalbumin-LHRH-7 compared to ovalbumin-treated heifers (P < .05). Serum progesterone concentrations (< 1 ng/mL) indicate that the estrous cycle of the four heifers treated with ovalbumin-LHRH-7 was suppressed for a time period ranging from 60 to 238 d, which was different from control heifers (P < .01). Serum progesterone for the control heifers continued to exhibit cyclic profiles over the experimental period. This preliminary study in heifers demonstrated that a chimeric LHRH fusion protein induced elevated concentrations of circulating LHRH antibodies that suppressed estrus for an average of 122 +/- 41 d.